Aurobindo Pharma’s board has approved the standalone and consolidated unaudited financial results for the quarter and half year ended September 30, 2025. The board meeting, held on November 5, 2025, reviewed and greenlit the financial performance reports, which have also undergone a limited review by the statutory auditors. Key figures from the financial results highlight the company’s operational and financial standing.
Financial Performance Highlights
Aurobindo Pharma’s standalone unaudited financial results show a revenue from operations of ₹27,897.2 million for the quarter ended September 30, 2025, and ₹56,378.9 million for the half year ended the same date. The profit after tax stands at ₹5,813.7 million for the quarter and ₹11,405.0 million for the half year.
Key Standalone Financial Metrics
Other key metrics from the standalone results include:
- Other income: ₹1,595.2 million for the quarter and ₹2,432.9 million for the half year.
- Total expenses: ₹21,939.6 million for the quarter and ₹43,758.1 million for the half year.
Consolidated Financial Results Overview
The consolidated unaudited financial results reveal a revenue from operations of ₹82,857.0 million for the quarter and ₹161,538.4 million for the half year ended September 30, 2025. Profit after tax reached ₹8,481.3 million for the quarter and ₹16,723.3 million for the half year.
Key Consolidated Financial Metrics
Key figures from the consolidated results include:
- Other income: ₹1,205.9 million for the quarter and ₹2,255.0 million for the half year.
- Total expenses: ₹71,320.3 million for the quarter and ₹139,002.0 million for the half year.
Earnings Per Share
The basic and diluted earnings per share for the quarter ended September 30, 2025, are reported as ₹10.01 on a standalone basis and ₹14.61 on a consolidated basis.
Source: BSE
